Lisinopril
Lisinopril is an ACE inhibitor (angiotensin-converting enzyme inhibitor), a medicine taken by mouth. The US label read, for ZESTRIL tablets (lisinopril), lists three uses: treating high blood pressure in adults (and, for pediatric patients 6 years and older, in a separate statement), adding to other treatment of heart failure to reduce signs and symptoms of systolic heart failure, and reducing deaths when started within 24 hours of an acute myocardial infarction in people whose condition is stable. Zestril is the brand name on the label read.
Also called Zestril
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 29046; UNII E7199S1YWR. The label describes the ingredient as lisinopril dihydrate, so UNII E7199S1YWR is the UNII of the dihydrate form and is a broad match. MeSH descriptor D017706 is Lisinopril. Class: Angiotensin Converting Enzyme Inhibitor (FDA established pharmacologic class, RxClass). The label read is the Upsher-Smith Laboratories, LLC label for ZESTRIL (lisinopril) tablets, application NDA019777, effective 2025-01-02 in openFDA; Drugs@FDA lists the application's sponsor as TWI PHARMS. Other lisinopril labels, including the Qbrelis oral solution label, were not read. This page records label indications and the class only: no trial result and no dose is given.
Trials at a glance
The figures count the 6 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.
- Trials
- 6
- Phase 3 or 4
- 5
- Recruiting
- 0
- Regulatory decisions
- 0
| Phase | Completed | Terminated | Unknown status | All statuses |
|---|---|---|---|---|
| Phase 2 | 1 | 0 | 0 | 1 |
| Phase 3 | 0 | 1 | 0 | 1 |
| Phase 4 | 2 | 1 | 1 | 4 |
| All phases | 3 | 2 | 1 | 6 |
Conditions these trials study
- Hypertension (high blood pressure)
- Chronic kidney disease (CKD)
- Coronary artery disease
- Diabetes mellitus
Sponsors with the most trials
About this drug
- Level
- Substance
- Mechanism
- Not reported
Classification codes
-
E7199S1YWR
Claims and evidence
Context Children for whom the US label of lisinopril (Zestril) lists hypertension as an indication: pediatric patients 6 years of age and older
- Recipient
- Child
- Population
- Children with hypertension, as the indications section of the label describes them. The same label sentence also names adults, who are recorded in a separate context.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Label wording: pediatric patients 6 years of age and older
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
- Included
- Children with hypertension (pediatric patients 6 years of age and older)
- Excluded
- None stated
The US label of ZESTRIL (lisinopril) tablets, in the Upsher-Smith Laboratories, LLC version dated 2025-01-02 in openFDA, lists the medicine for the treatment of hypertension in pediatric patients 6 years of age and older.
Applies to Child Children for whom the US label of lisinopril (Zestril) lists hypertension as an indication: pediatric patients 6 years of age and older
- Certainty method
- Not assessed
- Limitations
- This claim records what the label says the medicine is indicated for in children. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-09
- Next evidence check due
- Not scheduled
Sources and citations (2)
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
- How it applies
- The label sentence that names children in the hypertension indication, quoted in the research quote table.
- Retrieved
- Source effective date
- 2025-01-02
- Source state
- Current
- Version fingerprint
19d3c7aeb72318fb767e48d426a1cb5c0715b2f2de82e0028467c20b5e469335- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20250102.
- Retrieved
- Source effective date
- 2025-01-02
- Source state
- Current
- Version fingerprint
19d3c7aeb72318fb767e48d426a1cb5c0715b2f2de82e0028467c20b5e469335- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Context Patients for whom the US label of lisinopril (Zestril) lists an indication: adult hypertension, systolic heart failure, acute myocardial infarction within 24 hours
- Recipient
- Recipient not specified
- Population
- Patients described in the indications section of the label. The hypertension indication names adults (and, separately, pediatric patients 6 years and older); the heart failure and myocardial infarction indications do not state an age range.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Adults for hypertension, as the passage read states; not stated for the other indications
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 3 inclusion criteria; exclusion criteria not stated
- Included
- Adult patients with hypertension
- Patients with systolic heart failure, as adjunct therapy
- Hemodynamically stable patients within 24 hours of acute myocardial infarction
- Excluded
- None stated
The US label of ZESTRIL (lisinopril) tablets, in the Upsher-Smith Laboratories, LLC version dated 2025-01-02 in openFDA, lists the medicine for the treatment of hypertension in adults (the same label sentence also names pediatric patients, recorded separately); as adjunct therapy for heart failure, to reduce signs and symptoms of systolic heart failure; and for the reduction of mortality in hemodynamically stable patients within 24 hours of acute myocardial infarction.
Applies to Recipient not specified Patients for whom the US label of lisinopril (Zestril) lists an indication: adult hypertension, systolic heart failure, acute myocardial infarction within 24 hours
- Certainty method
- Not assessed
- Limitations
- This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-09
- Next evidence check due
- Not scheduled
Sources and citations (5)
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
- How it applies
- The label sentences that give the indications named in the statement, each quoted in the research quote table.
- Retrieved
- Source effective date
- 2025-01-02
- Source state
- Current
- Version fingerprint
19d3c7aeb72318fb767e48d426a1cb5c0715b2f2de82e0028467c20b5e469335- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[2], 1.2 Heart Failure
- How it applies
- The label sentences that give the indications named in the statement, each quoted in the research quote table.
- Retrieved
- Source effective date
- 2025-01-02
- Source state
- Current
- Version fingerprint
19d3c7aeb72318fb767e48d426a1cb5c0715b2f2de82e0028467c20b5e469335- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[3], 1.3 Reduction of Mortality in Acute Myocardial Infarction
- How it applies
- The label sentences that give the indications named in the statement, each quoted in the research quote table.
- Retrieved
- Source effective date
- 2025-01-02
- Source state
- Current
- Version fingerprint
19d3c7aeb72318fb767e48d426a1cb5c0715b2f2de82e0028467c20b5e469335- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20250102.
- Retrieved
- Source effective date
- 2025-01-02
- Source state
- Current
- Version fingerprint
19d3c7aeb72318fb767e48d426a1cb5c0715b2f2de82e0028467c20b5e469335- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].products[0].brand_name
- How it applies
- Drugs@FDA product listing for application NDA019777, which confirms the product the label belongs to.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
10404252bca5ef727ea05a4ea88c2e77deb09478b9d3791d6f5084684cf291f1- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short values are quoted. The raw record is committed in the atlas repository.
Pregnancy, lactation and children
The claims about this drug whose clinical context is a pregnancy, breastfeeding or a newborn, infant or child, grouped by that context. Each claim is also in Claims and evidence. A group with no claim is not shown, and an empty group does not mean the medicine is safe or unsafe there.
In newborns, infants and children 1
The US label of ZESTRIL (lisinopril) tablets, in the Upsher-Smith Laboratories, LLC version dated 2025-01-02 in openFDA, lists the medicine for the treatment of hypertension in pediatric patients 6 years of age and older.
Applies to Child Children for whom the US label of lisinopril (Zestril) lists hypertension as an indication: pediatric patients 6 years of age and older
Population, setting and follow-up
- Children with hypertension, as the indications section of the label describes them. The same label sentence also names adults, who are recorded in a separate context.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Label wording: pediatric patients 6 years of age and older
- Gestational age Not reported
- Postnatal age Not reported
- Certainty method
- Not assessed
- Limitations
- This claim records what the label says the medicine is indicated for in children. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-09
- Next evidence check due
- Not scheduled
Sources and citations (2)
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
- How it applies
- The label sentence that names children in the hypertension indication, quoted in the research quote table.
- Retrieved
- Source effective date
- 2025-01-02
- Source state
- Current
- Version fingerprint
19d3c7aeb72318fb767e48d426a1cb5c0715b2f2de82e0028467c20b5e469335- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20250102.
- Retrieved
- Source effective date
- 2025-01-02
- Source state
- Current
- Version fingerprint
19d3c7aeb72318fb767e48d426a1cb5c0715b2f2de82e0028467c20b5e469335- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
FDA label
The FDA label of the application holder, as the openFDA label dataset holds it, for the products that contain this drug.
PRINIVIL
No label from the application holder was found in the openFDA label dataset for application NDA019558. This page does not show another labeler's label in its place.
PRINZIDE
No label from the application holder was found in the openFDA label dataset for application NDA019778. This page does not show another labeler's label in its place.
QBRELIS
No label from the application holder was found in the openFDA label dataset for application NDA208401. This page does not show another labeler's label in its place.
ZESTORETIC
No label from the application holder was found in the openFDA label dataset for application NDA019888. This page does not show another labeler's label in its place.
ZESTRIL
No label from the application holder was found in the openFDA label dataset for application NDA019777. This page does not show another labeler's label in its place.
FDA decisions timeline
The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.
- Approval
NDA019558 - Approval
NDA019777 - Approval
NDA019778 - Approval
NDA019888 - Supplemental approval
NDA019777 - Supplemental approval
NDA019558 - Supplemental approval
NDA019778 - Supplemental approval
NDA019888 - Supplemental approval
NDA019558 - Supplemental approval
NDA019777 - Supplemental approval
NDA019777 - Supplemental approval
NDA019558 - Supplemental approval
NDA019777 - Approval
NDA208401
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact FDA label lists hypertension as an indication: Hypertension (high blood pressure)
Applies to Recipient not specified Patients for whom the US label of lisinopril (Zestril) lists an indication: adult hypertension, systolic heart failure, acute myocardial infarction within 24 hours
The US label of ZESTRIL (lisinopril) tablets, in the Upsher-Smith Laboratories, LLC version dated 2025-01-02 in openFDA, lists the medicine for the treatment of hypertension in adults (the same label sentence also names pediatric patients, recorded separately); as adjunct therapy for heart failure, to reduce signs and symptoms of systolic heart failure; and for the reduction of mortality in hemodynamically stable patients within 24 hours of acute myocardial infarction.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact FDA label lists adjunct therapy to reduce signs and symptoms of systolic heart failure as an indication: Heart failure
Applies to Recipient not specified Patients for whom the US label of lisinopril (Zestril) lists an indication: adult hypertension, systolic heart failure, acute myocardial infarction within 24 hours
The US label of ZESTRIL (lisinopril) tablets, in the Upsher-Smith Laboratories, LLC version dated 2025-01-02 in openFDA, lists the medicine for the treatment of hypertension in adults (the same label sentence also names pediatric patients, recorded separately); as adjunct therapy for heart failure, to reduce signs and symptoms of systolic heart failure; and for the reduction of mortality in hemodynamically stable patients within 24 hours of acute myocardial infarction.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact FDA label lists reduction of mortality in hemodynamically stable patients within 24 hours of acute myocardial infarction as an indication: Heart attack (myocardial infarction)
Applies to Recipient not specified Patients for whom the US label of lisinopril (Zestril) lists an indication: adult hypertension, systolic heart failure, acute myocardial infarction within 24 hours
The US label of ZESTRIL (lisinopril) tablets, in the Upsher-Smith Laboratories, LLC version dated 2025-01-02 in openFDA, lists the medicine for the treatment of hypertension in adults (the same label sentence also names pediatric patients, recorded separately); as adjunct therapy for heart failure, to reduce signs and symptoms of systolic heart failure; and for the reduction of mortality in hemodynamically stable patients within 24 hours of acute myocardial infarction.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Registry records
Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry products 5
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 3 efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 4 efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 1 efficacy supplement approval on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 1 efficacy supplement approval on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
Registry trials 6
Record details
- Record id
cardio:lisinopril- Content hash
3232d527bcb89d64232242a9c0fe287af3d04c449800c2e32589cb38310a826d